Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

This study is testing ruxolitinib, a drug that blocks certain inflammatory signaling pathways, as a treatment for T-cell large granular lymphocytic leukemia (T-LGLL) — a rare, slow-growing blood cancer. Most patients need treatment because the cancer suppresses normal blood cell production. **You may be eligible if...** - You are 18 years or older and can swallow pills - You have been diagnosed with T-LGLL confirmed by blood tests showing abnormal immune cell levels and a clonal T-cell receptor - You include rare variants such as CD4+ T-LGLL or gamma/delta T-LGLL **You may NOT be eligible if...** - Your white blood cell count (neutrophils) is very low (below 100/mm³) even after growth factor treatment - You have an active infection requiring antibiotics - You have HIV or active hepatitis Talk to your doctor to see if this trial is right for you.